June 15 (Reuters) - Endo Pharmaceuticals Inc ENDP.O :
* Has been notified that an advisory committee of FDA will
be convened in fall of 2016
* Advisory committee of FDA will be convened to review
company's supplemental new drug application (SNDA) for Opana ER
* Current prescription drug user fee act (PDUFA) date of
july 29, 2016 for Opana ER SNDA will not be met
Source text for Eikon: ID:nCNWbVGdka
Further company coverage: ENDP.O
(Bengaluru Newsroom: +1-646-223-8780)